ABSTRACT It has been suggested that in normal subjects inhaled 
100% after ipratropium but when assessed by air and helium/oxygen (He/02) flow-volume curves, responders and non-responders to He/02 breathing were divided equally between those who benefited from the drug, and those who did not. There were no significant differences in percentage improvement in Vmax between initial responders, and initial non-responders to He/02 breathing. Furthermore the results from air and He/02 flow-volume curves suggest that, contrary to some previous reports (not in asthmatics), inhaled ipratropium has a generalised action throughout the airways. There were no differences in severity of airflow obstruction, nor in age, sex, smoking history, or atopic status between those who benefited from ipratropium and those who did not. However, those improving after the drug had a significantly longer history of asthma than those who did not.
Although resting vagal tone is normally present throughout the bronchial tree,' it has been claimed that in normal subjects inhaled anticholinergic agents act mainly on the large central airways,'-3 although Douglas and colleagues4 disagree.
In some patients with asthma the helioxygen technique5 suggests that the major site of narrowing is in the larger central airways, whereas in others the main obstruction is more peripheral.
If the anticholinergic agent ipratropium acts mainly on large airways, it should be more effective in patients with predominant large airway obstruction, and this is the hypothesis tested here. The use of the helioxygen technique to test the effect of ipratropium in asthmatic patients has not been reported previously.
Methods
Twenty-one patients with airflow obstruction which had been shown to vary spontaneously or with treatment took part in the study and their clinical details are shown in table 1. Atopic status and smoking status were categorised in the same way as by Antic and Macklem. 6 All patients attended the laboratory in an afternoon having had no bronchodilator for at least 12 hours. Flow Those with a greater than 20% response to He/02 breathing were termed "responders" and those with a less than 20 % response termed "non-responders". 5 The patients then inhaled four puffs of ipratropium bromide (0-08 mg) and air and He/02 flow-volume curves were repeated 30 Vmax,0 and Vmax20 refer to maximum flow rates at 50 and 25°% of vital capacity. There were no differences in severity of airflow obstruction, nor in age, sex, smoking history, or atopic status between the 14 patients who benefited from ipratropium and those who did not. However, those improving after the drug had a significantly longer history of asthma (mean 20-4 years + 19'9) than those who did not improve (mean 6&2 years + 10,2, unpaired t test p < 0'05).
Discussion
The technique of comparing air and He/O3 flowvolume curves is a widely accepted method of determining the main site of airway narrowing, and the theoretical background5 7 is supported by validation in dogs.8 However, the actual size of airways where a laminar and therefore density independent flow regime prevails may be surprisingly large.9 Using this technique, Ingram and colleagues2 have suggested that in normal subjects inhalation of anticholinergic agents is associated with preferential large airway dilation. Hensley and colleagues3 have measured anatomical dead space before and after inhaled atropine in normal subjects, and reviewed published reports to suggest that this measurement is weighted towards dimensional changes in the more proximal conducting airways. They have shown increases in anatomical dead space after atropine and interpret the findings (by a comparison with the peripheral effects of isoprenaline) to confirm that the predominant site of action of inhaled atropine is on the larger central airways. De Troyer and colleagues' have compared the effects of large doses of inhaled ipratropium bromide with those of intravenous atropine, and suggested that the bronchodilation produced by the inhaled drug is confined to the large airways, whereas intravenous atropine has an additional peripheral airway effect.
In our 21 patients with asthma the mean density dependence (AVmax50 % He/02) after ipratropium was the same as before inhalation of the drug. This suggests that there was no systematic change in the site in the airways at which maximum flow is determined (the flow-limiting segment bronchitis respond well to ipratropium bromide.'0 Some of our patients with asthma had chronic productive cough-although we did not formally assess these symptoms-but parallel work from this laboratory" suggests that the presence of a chronic productive cough in patients with asthma does not distinguish responders to ipratropium.
In conclusion, results of this study suggest that, contrary to some previous work in normal subjects' 3 the action of ipratropium in patients with asthma is one of generalised bronchodilation of the tracheobronchial tree, but this conclusion is in agreement with other studies in normal subjects and in patients with chronic bronchitis.4 10 Helioxygen MEFV curves do not give information which enable the response to ipratropium to be predicted. 
